| Literature DB >> 32421074 |
Prashant Saxena1,2, Sanjay Mishra2.
Abstract
Chikungunya is a mosquito-borne disease, caused by the member of the Togaviridae family belongs to the genus alphavirus, making it a major threat in all developing countries as well as some developed countries. The mosquito acts as a vector for the disease and carries the CHIK-Virus. To date there is no direct treatment available and that demands the development of more effective vaccines. In this study author employed Immune Epitope Database and Analysis Resource, a machine learning-based algorithm principally working on the Artificial Neural Network (ANN) algorithm, also known as (IEDB-ANN) for the prediction and analysis of Epitopes. A total of 173 epitopes were identified on the basis of IC50 values, among them 40 epitopes were found, sharing part with the linear B-cell epitopes and exposed to the cTAP1protein, and out of 40, 6 epitopes were noticed to show interactions with the cTAP with their binding energy ranging from - 3.61 to - 1.22 kcal/mol. The six epitopes identified were exposed to the HLA class I alleles and from this all revealed interaction with the HLA alleles and minimum binding energy that ranges from - 4.12 to - 5.88 kcal/mol. Besides, two T cell epitopes i.e. 145KVFTGVYPE153 and 395STVPVAPPR403 were found most promiscuous candidates. These promiscuous epitopes-HLA complexes were further analyzed by the molecular dynamics simulation to check the stability of the complex. Results obtained from this study suggest that the identified epitopes i.e. and 395 STVPVAPPR 403 , are likely to be capable of passing through the lumen of ER to bind withthe HLA class I allele and provide new insights and potential application in the designing and development of peptide-based vaccine candidate for the treatment of chikungunya. © Springer Nature B.V. 2020.Entities:
Keywords: Chikungunya; Docking; Epitope; HLA; Immunoinformatics; NAMD; Vaccine; cTAP
Year: 2020 PMID: 32421074 PMCID: PMC7223317 DOI: 10.1007/s10989-020-10038-2
Source DB: PubMed Journal: Int J Pept Res Ther ISSN: 1573-3149 Impact factor: 1.931
Fig. 1Workflow of the top-down approach of immunoinformatics, to employ the prediction of Chikungunya vaccine
Identified HLA Class I epitopes of CHIKV structural protein and their analysis
| S. no | T cell epitope (start–end position) | HLA allele | Protein | IC50 value (nM) | B cell epitope property | Conservancy (%) | TAP binding score |
|---|---|---|---|---|---|---|---|
| 1 | LQISFSTAL | A-0206 | E1 | 6.8 | No | 100 | 4.076 |
| 2 | TVIPNTVGV | E1 | 11.11 | Yes (0.912) | 100 | 4.238 | |
| 3 | FIVGPMSSA | E1 | 14.19 | No | 100 | 7.704 | |
| 4 | SLTDMSCEV | E1 | 18.99 | No | 100 | 5.689 | |
| 5 | YSCKVFTGV | E1 | 19.3 | No | 100 | 8.145 | |
| 6 | KVFTGVYPF | E1 | 26.55 | Yes (0.819) | 100 | 3.841 | |
| 7 | SQLQISFST | E1 | 30.02 | No | 100 | 5.026 | |
| 8 | KTVIPSPYV | E1 | 49.82 | No | 100 | 3.959 | |
| 9 | TVIPSPYVK | A-1101 | E1 | 10.18 | No | 100 | 3.984 |
| 10 | SAWTPFDNK | E1 | 18.31 | No | 100 | 3.865 | |
| 11 | TVIPSPYVK | A-6801 | E1 | 14.61 | No | 100 | 3.984 |
| 12 | HAAVTNHKK | E2 | 17.66 | No | 100 | Non-binder | |
| 13 | ITVNGQTVR | E2 | 25 | No | 100 | Non-binder | |
| 14 | FTIPTGAGK | C | 8.79 | Yes (1.0) | 100 | Non-binder | |
| 15 | DASKFTHEK | C | 18.27 | No | 100 | Non-binder | |
| 16 | VYNMDYPPF | A-2402 | E1 | 32.56 | No | 100 | 6.568 |
| 17 | QYNSPLVPR | A-3101 | E2 | 12.18 | No | 100 | Non-binder |
Identified HLA Class I epitopes of CHIKV non-structural protein and their analysis
| S. no | T cell epitope (start–end position) | HLA allele | Protein | IC50 value (nM) | B cell epitope property | Conservancy (%) | TAP binding score (nM) |
|---|---|---|---|---|---|---|---|
| 1 | FVVPSLWSS | A-0206 | nSP-1 | 4.85 | No | 100 | 3.092 |
| 2 | VQAEFDSFV | nSP-1 | 5.93 | No | 100 | Non-Binder | |
| 3 | AIYQDVYAV | nSP-1 | 12.19 | No | 100 | 5.832 | |
| 4 | YQDVYAVHA | nSP-1 | 13.37 | No | 100 | Non-binder | |
| 5 | IIVCSSFPL | nSP-3 | 8.78 | No | 100 | 3.249 | |
| 6 | WVMSTVPVA | nSP-3 | 45.98 | No | 100 | Non-binder | |
| 7 | TQMRELPTL | nSP-4 | 13.2 | No | 100 | 6.178 | |
| 8 | ITDEYDAYL | nSP-4 | 41.71 | No | 100 | 3.254 | |
| 9 | MTFDTFQNK | A-1101 | nSP-2 | 9.99 | No | 100 | 3.133 |
| 10 | SSFPLPKYK | nSP-3 | 8.28 | No | 100 | 5.117 | |
| 11 | STVPVAPPR | nSP-3 | 22.58 | Yes (1.0) | 100 | 3.662 | |
| 12 | MTFDTFQNK | A-6801 | nSP-2 | 7.06 | No | 100 | 3.133 |
| 13 | YVYDVDQRR | nSP-2 | 8.84 | No | 100 | 5.690 | |
| 14 | ITTDVMRQR | nSP-2 | 22.9 | No | 100 | 3.384 | |
| 15 | STVPVAPPR | nSP-3 | 9.18 | Yes (1.0) | 100 | 3.662 | |
| 16 | CVVNAANPR | nSP-3 | 19.13 | Yes (0.999) | 100 | 4.720 | |
| 17 | SSFPLPKYK | nSP-3 | 37.1 | No | 100 | 5.117 | |
| 18 | LTTYVTKLK | nSP-4 | 17.91 | No | 100 | Non-binder | |
| 19 | VYKKWPESF | A-2402 | nSP-3 | 12.37 | No | 100 | 5.399 |
| 20 | KYHCVCPMR | A-3101 | nSP-1 | 8.84 | No | 100 | Non-binder |
| 21 | KQICVTTRR | nSP-2 | 14.32 | No | 100 | 4.165 | |
| 22 | STVPVAPPR | nSP-3 | 44.48 | Yes (1.0) | 100 | 3.662 | |
| 23 | NMKATIIQR | nSP-4 | 14.38 | No | 100 | 5.856 |
Fig. 2Modelled structure of HLA class I alleles. a Molecular structure of HLA-A*02:06 allele and b Molecular structure of HLA-A*31:01 allele
Comparative quality analysis of modelled structure by different computational tool
| S. no | HLA allele HLA-A* | aVerify 3D | bERRAT | cPROVE | dProCheck E W P | eProSa | fPROQ | gRAMPAGE |
|---|---|---|---|---|---|---|---|---|
| 1 | 02:06 | 98.18 | 94.4223 | 2.8 | 0 6 3 | − 9.14 | 2.981 | ~ 98.9 |
| 2 | 11:01 | 99.64 | 91.5709 | 3.8 | 4 3 2 | − 8.87 | 2.369 | ~ 95.6 |
| 3 | 31:01 | 98.55 | 98.4848 | 2.3 | 1 5 3 | − 8.92 | 2.630 | ~ 98.2 |
| 4 | 68:01 | 99.27 | 98.4906 | 2.3 | 0 6 3 | − 9.32 | 2.811 | ~ 97.4 |
aAt least 80% amino acid residue must have 3D score ≥ 0.2
bIt defines the quality factor of the modelled protein structure
cOn the basis of Voronai radical planes predicts the quality of the structure
dDefines the available error warning and pass of the modelled structure
eThe quality of the modelled structure is predicted in terms of Z score
fThe quality of the modelled score is predicted in terms of LG score
gThe data represents the number of amino acids available in the favored region in the Ramachandran plot
Fig. 3The Ramachandran plot of the modelled structure generated by the SAVES server topredict the stability of the modelled structure of protein molecules. a The modelled protein structure of HLA-A*02:06 has 93.4% amino acid residue in the favored region while 0.0% amino acid residue falls in the disallowed region. b The modelled protein structure of HLA-A*31:01 has 93.0% amino acid residue in the favored region while 0.0% amino acid residue falls in the disallowed region
Fig. 4The Superimposition model of HLA class I alleles. Each color represents a different HLAallele. The green color shows HLA-A*68:01, Violet color shows HLA-A*31:01, Blue color shows HLA-A*11:01 and Brown color shows the structure of HLA-A*02:06 respectively
Molecular docking analysis of identified epitope & cTAP1 protein and their interaction analysis
| S. no | Epitope & cTAP1 | EBinding (Kcal/Mol) | Ki (mM) | RMSD (Å) | H-bonds | H-bond distance (Å) |
|---|---|---|---|---|---|---|
| 1 | KVFTGVYPE | − 1.41 | 92.34 | 139.738 | GLY585–TYR7 | 2.62 |
| GLN586–THR4 | 3.18 | |||||
| GLU587–VAL2 | 2.55 | |||||
| TYR555–PHE9 | 3.31 | |||||
| GLY585–VAL5 | 2.66 | |||||
| GLN552–ARG9 | 3.07 | |||||
| 2 | STVPVAPPR | − 3.99 | 1.18 | 144.162 | GLN586–SER1 | 3.35 |
| ALA583–PRO8 | 2.80 | |||||
| HIS574–ARG9 | 2.85 |
Molecular docking analysis of identified epitope &HLA class I allele and their interaction analysis
| S. no | Epitope & HLA | Ebinding (Kcal/Mol) | Ki (µM) | RMSD (Å) | H-bonds | H-bond distance (Å) |
|---|---|---|---|---|---|---|
| 1 | TVIPNTVGV & HLA-A*02:06 | − 4.58 | 442.19 | 18.547 | THR34–VAL9 | 2.9 |
| GLN120–VAL7 | 3.3 | |||||
| THR257–THR1 | 2.8 | |||||
| GLU256–THR1 | 2.7 | |||||
| TYR51–TLE3 | 3.9 | |||||
| PHE32–ILE3 | 3.3 | |||||
| 2 | KVFTGVYPE & HLA-A*02:06 | − 5.88 | 48.89 | 17.411 | SER28–PHE3 | 3.0 |
| ARG30–THR4 | 2.8 | |||||
| THR34–PHE9 | 2.3 | |||||
| GLN120–PHE9 | 2.8 | |||||
| ASP54–VAL6 | 2.7 | |||||
| 3 | STVPVAPPR & HLA-A*11:01 | − 4.64 | 395.95 | 100.402 | ARG30–PRO4 | 2.5 |
| TYR51–THR2 | 3.21 | |||||
| TYR137–ARG9 | 3.27 | |||||
| PHE32–VAL3 | 3.98 | |||||
| 4 | STVPVAPPR & HLA-A*31:01 | − 5.65 | 72.42 | 75.956 | ASP146–ARG9 | 3.57 |
| THR34–PRO7 | 2.66 | |||||
| TYR51–THR2 | 2.39 | |||||
| GLN120–PRO7 | 3.24 | |||||
| GLY261–SER1 | 2.69 | |||||
| ASP54—VAL3 | 2.88 | |||||
| 5 | CVVNAANPR & HLA-A*68:01 | − 5.39 | 112.20 | 70.891 | GLU256–ARG9 | 2.67 |
| SER28–VAL5 | 2.70 | |||||
| ASP54–SER1 | 3.17 | |||||
| PHE265–PRO8 | 3.61 | |||||
| 6 | STVPVAPPR & HLA-A*68:01 | − 4.12 | 950.29 | 64.03 | ASP54–ARG9 | 3.19 |
| TYR51–ASN7 | 2.93 | |||||
| GLN121–VAL3 | 2.57 |
Binding energy = intermolecular energy + Vander wall’s energy + De-solvation energy + electrostatic energy
Ki = inhibition constant (µM)
RMSD deviation in the molecular structure from its reference structure (Å)
Distance of H bonds length of the bond between the donor and acceptor atom
Fig. 5Interaction complex of epitope & HLA. a Depicts the interaction analysis of E1envelope glycoprotein epitope KVFTGVYPE-HLA-A*02:06 complex. Showing the epitope-interacting with HLA molecule in the binding groove, clearly showing the 5 H-bonds in the HLA pocket. b It depicts the interaction analysis of the nsp3 epitope-HLA complex. Showing the STVPVAPPR-HLA-A*31:01 complex with 6 H-bonds
Fig. 6The Energy vs TS and RMSD vs Time graph for theKVFTGVYPE– HLA-A*02:06Complex obtained by the simulation study by NAMD-VMD tool
Fig. 7The Energy vs TS and RMSD vs Time graph for theSTVPVAPPR– HLA-A*31:01 Complex obtained by the simulation study by NAMD-VMD tool